Maiwei Biotech (688062.SH): Application for clinical trial of injection 6MW5311 approved by FDA
Maiwei Biotech (688062.SH) announced that the company has recently received a "Notice of Continuation of Clinical Research" issued by the US Food and Drug Administration (FDA). The clinical trial application for the use of injection 6MW5311 in the indications of hematologic malignancies (acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM)) has officially been approved by the FDA.
Maiwei Biotechnology (688062.SH) announced that the company has recently received a "Notice of Continuation of Clinical Research" issued by the Food and Drug Administration (FDA) of the United States. The clinical trial application for injection use of 6MW5311 in the treatment of hematologic malignancies (Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), and Multiple Myeloma (MM)) has officially obtained FDA approval.
In addition, the clinical trial application for 6MW5311 has been accepted by the National Medical Products Administration. 6MW5311 is the world's first targeted LILRB4/CD3 TCE innovative drug to be approved for clinical trials.
Related Articles
SpaceX and Charter are in talks to collaborate on mobile phone services, with the satellite giant accelerating its entry into the consumer-level communication market.
Apple Inc. (AAPL.US) suffers another major loss: Vision Pro executive joins OpenAI, escalating the competition for talent in the AI field.
.png)
HK Bull/Bear Outstanding Qty Ratio(55:45) | June 27th
SpaceX and Charter are in talks to collaborate on mobile phone services, with the satellite giant accelerating its entry into the consumer-level communication market.
Apple Inc. (AAPL.US) suffers another major loss: Vision Pro executive joins OpenAI, escalating the competition for talent in the AI field.
HK Bull/Bear Outstanding Qty Ratio(55:45) | June 27th
RECOMMEND
